Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Cidara Therapeutics, Inc.

$221.38

+0.06 (+0.03%)

D 38Pipeline Score Richly Valued Biotech · Commercial
Market Cap
6.96 B
EPS
-11.78
P/E Ratio
-
Value Trade
595.72 M
SEC Financials
Q3 2025

  • Dilution Risk

    60%

  • Revenue

    -

  • R&D Expenses

    35.53 M

  • Total Assets

    518.65 M

  • Total Liabilities

    96.26 M

  • Equity

    422.39 M

  • D/E Ratio

    12,345

0.35 %
Week
0.53 %
1 Month
116.42 %
3 Month
335.1 %
6 Month
407.75 %
5 Year
-31.29 %
All Time
Cash Data
Caution

  • Cash Position

    420.02 M

  • Monthly Burn

    29.54 M

  • Runway

    6.2 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    Nov 6, 2025
Overview
Volume
2.69 M
52 Week Range
15.22 - 221.42
% held by Insiders
40.83 %
% held by Institutions
41.78 %
Enterprise Value
6.54 B
Total Shares
31.42 M
Short %
8.77 %
Float Shares
21.46 M
Company Description

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D38
Pipeline Score
$971M
Pipeline Value
Richly Valued
Valuation Signal
4
Drugs Scored
0.1x
rNPV / MCap
Top 53%
Small Cap
(rank 429 of 911)
Percentile Rank
Cidara Therapeutics, Inc. faces pipeline headwinds (38/100), with $1.5B risk-adjusted pipeline value, led by Rezafungin in Candidemia (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Rezafungin
Small molecule		CandidemiaPhase 3NCT0366769056% $962M COMPLETED 199 - -Oct 7, 2021 -Jan 6, 2023
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
CD388
BreakthroughFast Track
universal prevention of seasonal and pandemic influenza
Phase 2b
2025-10-28

positive top-line results

Cidara Therapeutics to Participate in November Investor Conferences

Read More
CD388
BreakthroughFast Track
universal prevention of seasonal and pandemic influenza
Phase 2b
2025-10-28

positive top-line results

Cidara Therapeutics to Participate in November Investor Conferences

Read More
CD388
BreakthroughFast Track
universal prevention of seasonal and pandemic influenza
Phase 2b
2025-10-28

positive top-line results

Cidara Therapeutics to Participate in November Investor Conferences

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in CDTX
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
CDTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How CDTX ranks across every disease it competes in
Competitive Position is a premium feature
See how CDTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial